Inovio Pharmaceuticals, Inc. Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc.

INO

株式のランク #23441
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research,... Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.
株価
$1.02
最終同期: 2026-10-20
時価総額
$70.13M
変化（1日）
1.50%
変化（1年）
-87.38%
国
US
取引 Inovio Pharmaceuticals, Inc. (INO)

カテゴリー

Healthcare
Inovio Pharmaceuticals, Inc.（INO）の株式分割履歴
Inovio Pharmaceuticals, Inc.株（シンボル：INO）は合計で0回の株式分割を実施しました。
最新の株式分割はOct 21, 2026に行われました。
Oct 21, 2026より前に購入されたINO株は、現在0INO株に相当します。
株式分割一覧
年 株式分割 分割比率 累積分割比率
提供された日付のデータは十分ではありません。
類似企業または競合他社の株式分割
企業 株式分割の回数 累積分割比率 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 1 x2
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 0 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 1 x3
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 0 -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
 0 -
NL